Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.
We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.
We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.
Report Feb. 22 2024
Committee: Health, Social Care and Sport CommitteeFound: worst it was feared that this approach can lead to cuts to social care packages or reduced support.14 Parkinson's
Asked by: Preet Kaur Gill (Labour (Co-op) - Birmingham, Edgbaston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will issue guidance to care settings on how to (a) support and (b) maintain contact between Parkinsons’ patients and their family members and carers.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Visits from loved ones are vital to the health and wellbeing of people receiving care in care homes, hospitals and hospices. In December 2023, the Government laid before Parliament the Health and Social Care Act 2008 (Regulated Activities) (Amendment) Regulations 2023, which adds visiting and accompanying as a new fundamental standard for the Care Quality Commission (CQC) to inspect care and health settings against. These regulations will come into force on 6 April 2024.
The CQC is now consulting on its proposed guidance for this legislation, which will help the health and social care sector understand and meet the new standard on visiting and accompanying in care homes, hospitals, and hospices and their roles and responsibilities under it. The guidance also sets out what people using health and social care services and their families, friends or advocates can expect. The consultation can be found at the following link:
Jan. 18 2024
Source Page: An independent review of English public libraries - report and government reponseFound: English public libraries HTML An independent review of English public libraries - Lord Parkinson's
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022Found: Paraplegia 2 0 Peripheral paralysis 1 0 Quadriparesis 1 0 Quadriplegia 1 0 Parkinson's
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 28 November 2022Found: Hemiparesis 6 0 Hemiplegia 1 0 Paralysis 9 0 Paraplegia 1 0 Quadriparesis 1 0 Parkinson's
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 28 November 2022Found: Paraesthesia 41 0 Paralysis and paresis (excl cranial nerve) Hemiparesis 3 0 Paralysis 6 0 Parkinson's
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 5 September 2022Found: - PROVISION OF RESULTS OF LONG -TERM SAFETY DATA FOR PARKINSON'S DISEASE (PD) WHICH WERE ONGOING
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 29 August 2022Found: Hypoaesthesia 6 0 Paraesthesia 9 0 Paralysis and paresis (excl cranial nerve) Paralysis 1 0 Parkinson's